Astellas Reports Less-Than-Stellar Results of Menopause Drug Trial

Astellas of Tokyo, Japan, has announced that its investigational nonhormonal menopause treatment fezolinetant did not meet its endpoints for efficacy at the halfway point of its phase 3 study of 302 patients in Asia.

The company didn't divulge the endpoints but said the selective neurokinin-3 receptor agonist is being studied for its potential to treat moderate-to-severe vasomotor symptoms associated with menopause, including hot flashes and night sweats.

Astellas said detailed results will be submitted for publication following completion of the 24-week analyses.